The National Institutes of Health has awarded $7.2 million to a Cleveland Clinic-led research team to improve accuracy of multiple sclerosis (MS) diagnoses.
The grant will support a multi-center study to evaluate whether a new biomarker, known as the central vein sign (CVS), can serve as a reliable diagnostic marker for MS. The study is funded through the National Institutes of Neurological Disorders and Stroke’s Clinical Validation of a Candidate Biomarker for Neurological Disease Program Announcement.
“Up to 20% of MS diagnoses turn out to be inaccurate,” said the study’s co-principal investigator, Daniel Ontaneda, M.D., Ph.D., of Cleveland Clinic’s Mellen Center for Multiple Sclerosis. “Our new multicenter study aims to reduce that number by evaluating if this new biomarker can improve diagnostic accuracy and simplify clinical decision-making.”
The prospective study, referred to as CAVS-MS, will enroll 400 patients with typical or atypical presentations of MS at 11 participating centers in North America, with Cleveland Clinic serving as the coordinating center. The study is being conducted under the auspices of the North American Imaging in MS Cooperative and will be led by Dr. Ontaneda and Dr. Nancy Sicotte, at Cedars-Sinai in Los Angeles.
The CVS is an MRI-based biomarker identified in MS-associated white matter lesions. CVS criteria — scoring of a brain MRI based on the presence of the CVS — have been well validated as a sensitive and specific marker of MS in cross-sectional studies.
“We aim to show that the CVS is a simple and reliable diagnostic biomarker that can be immediately translated into clinical care,” Dr. Ontaneda explains. “We are evaluating if this sign can improve sensitivity and specificity relative to current approaches and streamline the clinical decision-making process.”
The need for improved diagnostic methods in MS is widely recognized. Although MRI is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist. Up to 1 in 5 people diagnosed with MS are later found not to have the disease, Dr. Ontaneda notes.
Currently the diagnosis of MS is based on criteria that are uninformative for the nearly half of MS patients with atypical presentations. Timeliness of diagnosis is also key, as diagnostic delay is common in relapsing-remitting MS and can carry severe and lifelong consequences.
The primary objective is to determine whether use of CVS criteria allows for an earlier accurate diagnosis of MS in patients who do not meet the McDonald criteria at baseline.
The researchers will also begin exploratory studies of optimal methods for integrating CVS findings into MS diagnostic criteria, along with any resulting healthcare-related cost savings.
“These initial exploratory analyses will be important to how readily positive findings about the utility of CVS criteria can impact clinical practice,” says Dr. Ontaneda. “The ultimate goal is to have the CVS incorporated into the MS diagnostic criteria.”